Zura Bio Limited Class A (ZURA)

Over the past six months, Zura Bio reported its full-year 2025 financial results, indicating increased R&D spending and a net loss, but an equity offering extended its cash runway. The company completed an underwritten equity offering, raising approximately $144 million. Zura Bio provided business updates and its outlook for 2026, announcing expanded enrollment for the Phase 2 TibuSHIELD study and updated timelines for topline data readouts. The company reported its third-quarter 2025 financial results, highlighting the advancement of its Phase 2 clinical trials for tibulizumab and reporting $139.0 million in cash and cash equivalents. The stock price has shown significant volatility and growth.

As a clinical-stage biotechnology company, demand seasonality does not directly apply to Zura Bio Ltd. The demand for its work is driven by the continuous unmet medical need for effective treatments for chronic autoimmune and inflammatory diseases, which is not subject to seasonal fluctuations.

Zura Bio Ltd. is a clinical-stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases. Their pipeline includes Tibulizumab (ZB-106), a bispecific antibody in Phase 2 trials for systemic sclerosis and hidradenitis suppurativa; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R, being evaluated across various autoimmune and inflammatory conditions; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33, also being assessed for autoimmune and inflammatory conditions.

Zura Bio Ltd. is headquartered in Henderson, Nevada, United States, and has a global team with members in both the UK and the USA.

Zura Bio Ltd.'s reputation has been shaped by its progress in clinical trials, financial updates, and corporate developments. Communications emphasize dedication to developing novel medicines for unmet medical needs in autoimmune and inflammatory diseases. There is no readily available information detailing specific events that have negatively impacted Zura Bio Ltd.'s brand reputation.

Zura Bio Ltd.'s ownership is a mix of institutional, insider, and public/individual investors. Institutional investors hold approximately 35.62% to 61.24% of the company's stock, insiders own about 12.82%, and public companies and individual investors hold between 17.76% and 49.31%. Major institutional owners include Suvretta Capital Management, Llc, VR Adviser, LLC, and Jpmorgan Chase & Co. AI Biotechnology LLC owns the most shares.